SpeechVive

Executive Summary

SpeechVive addresses a critical unmet need in Parkinson's disease management: hypophonia (soft speech). Its wearable device, resembling a behind-the-ear hearing aid, emits a subtle noise that automatically triggers the brain's Lombard effect, causing individuals to speak louder and more clearly without conscious effort. This provides immediate, clinically meaningful improvement in communication, reducing social isolation and fall risk associated with voice impairment. Unlike intensive speech therapy, the device works passively and can be used daily. As an FDA-registered Class I medical device, it has a streamlined regulatory path and is already reimbursed by Medicare, the VA, and select commercial insurers. The company is well-positioned to scale given its established reimbursement and a large, underserved patient population (over 1 million in the US with Parkinson's-related speech issues). Key growth drivers include expanding commercial insurance coverage, generating additional clinical evidence to support broader adoption, and forging partnerships with neurology clinics and rehabilitation centers. With a low-risk regulatory status and a proven revenue model, SpeechVive offers a practical, high-impact solution that improves quality of life for Parkinson's patients. Its lean operations and clear value proposition make it a compelling investment in the digital health and neuroscience space.

Upcoming Catalysts (preview)

• Q4 2026Expansion of commercial insurance coverage to major national carriers60% success
• Q1 2027Publication of peer-reviewed clinical outcomes study demonstrating long-term efficacy50% success
• Q2 2027Partnership or distribution agreement with a large neurology practice group40% success